Back to search

Article

Resistance to anti-orthopoxviral drug tecovirimat (TPOXX<sup>®</sup>) during the 2022 mpox outbreak in the US

2023-05-18

Abstract excerpt

<h4>Background</h4> During the 2022 multinational outbreak of monkeypox virus (MPXV) clade IIb, the antiviral drug tecovirimat (TPOXX ® ) was deployed in the US on a large scale for the first time ever. The MPXV F13L gene homolog encodes the target of tecovirimat, and single amino acid changes in the F13 protein are known to cause resistance to tecovirimat in orthopoxviruses (OPXV). <h4>Methods</h4> Whole genome m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5275a817-ad0a-5bd0-b819-dccdc6958792
DOI
10.1101/2023.05.16.23289856
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Resistance to anti-orthopoxviral drug tecovirimat (TPOXX<sup>®</sup>) during the 2022 mpox outbreak in the USDOI 10.1101/2023.05.16.23289856
Select a neighboring publication to make it the new centre.